NCT00496132View on ClinicalTrials.gov

A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 27, 2007

Primary Completion Date

June 17, 2009

Study Completion Date

June 17, 2009

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

PRO131921

Escalating doses by IV infusion

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY